TScan Therapeutics’ (TCRX) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a report issued on Tuesday morning, RTT News reports. They currently have a $10.00 price target on the stock.

A number of other analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research note on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Trading Up 4.1 %

Shares of TCRX stock opened at $5.29 on Tuesday. TScan Therapeutics has a 1 year low of $3.73 and a 1 year high of $9.69. The firm’s fifty day simple moving average is $5.35 and its 200 day simple moving average is $6.60. The company has a quick ratio of 7.77, a current ratio of 7.77 and a debt-to-equity ratio of 0.08.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. Analysts expect that TScan Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Barbara Klencke acquired 5,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the completion of the purchase, the director now owns 35,000 shares of the company’s stock, valued at $199,150. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased 15,000 shares of company stock worth $82,550 in the last 90 days. 2.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On TScan Therapeutics

A number of large investors have recently bought and sold shares of TCRX. Tocqueville Asset Management L.P. bought a new stake in shares of TScan Therapeutics during the first quarter worth $1,685,000. Bank of Montreal Can acquired a new position in TScan Therapeutics during the 2nd quarter worth about $749,000. Bank of New York Mellon Corp bought a new stake in TScan Therapeutics during the 2nd quarter worth about $682,000. Great Point Partners LLC acquired a new stake in TScan Therapeutics in the 2nd quarter valued at about $5,504,000. Finally, Marshall Wace LLP raised its stake in shares of TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after acquiring an additional 116,316 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.